COST MINIMIZATION COMPARISON OF A VACCINATION WITH CAMPAIGN PROGRAM FOR CORPORATIONS USING PCV13 VESUS FREE PCV10 WITH PAID CAMPAIGN

被引：0
|
作者：
Fujii, R. K. [1 ]
Mould, J. [2 ]
Roberts, C. S. [2 ]
Presa, J. [3 ]
Jardim, E. [3 ]
机构：
[1] Pfizer Inc, Sao Paulo, Brazil
[2] Pfizer, New York, NY USA
[3] Pfizer Parmaceut Inc, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A397 / A397
页数：1
相关论文
共 21 条
  • [1] Comparing the effect of PCV10 and PCV13 paediatric vaccination programmes
    Theilacker, Christian
    Fletcher, Mark A.
    Spinardi, Julia R.
    Jodar, Luis
    Gessner, Bradford D.
    LANCET INFECTIOUS DISEASES, 2021, 21 (02): : 170 - 171
  • [2] Comparing the effect of PCV10 and PCV13 paediatric vaccination programmes Reply
    Agudelo, Clara Ines
    Castaneda-Orjuela, Carlos
    Di Fabio, Jose Luis
    Castaneda, Elizabeth
    LANCET INFECTIOUS DISEASES, 2021, 21 (02): : 171 - 172
  • [3] BUDGET IMPACT EVALUATION OF A PNEUMOCOCCAL CONJUGATED VACCINE (PCV) 13 VALENT VACCINATION WITH FREE CAMPAIGN PROGRAM FOR CORPORATIONS VESUS NO VACCINATION FOR OLDER ADULTS
    Fujii, R. K.
    Presa, J.
    Roberts, C. S.
    Gea, Y.
    Manfrin, D. F.
    Mould, J.
    VALUE IN HEALTH, 2013, 16 (03) : A84 - A84
  • [4] Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach?
    Desmet, Stefanie
    Verhaegen, Jan
    Van Ranst, Marc
    Peetermans, Willy
    Lagrou, Katrien
    LANCET INFECTIOUS DISEASES, 2018, 18 (08): : 830 - 831
  • [5] Interpretation of the switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10 in Belgium
    Izurieta, Patricia
    Breuer, Thomas
    LANCET INFECTIOUS DISEASES, 2018, 18 (08): : 831 - 832
  • [6] COST EFFECTIVENESS ANALYSIS OF VACCINATION PROGRAMS WITH 10-VALENT (PCV10) AND 13-VALENT (PCV13) PNEUMOCOCCAL VACCINES IN COLOMBIA
    Coronel, W.
    Jaramillo, J.
    Caceres, H. A.
    Riveros, L.
    VALUE IN HEALTH, 2011, 14 (03) : A117 - A117
  • [7] How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country
    Castaneda-Orjuela, Carlos
    De la Hoz-Restrepo, Fernando
    VACCINE, 2018, 36 (38) : 5766 - 5773
  • [8] COST EFFECTIVENESS ANALYSIS OF VACCINATION PROGRAMS WITH 10-VALENT (PCV10) AND 13-VALENT (PCV13) PNEUMOCOCCAL VACCINES IN BOGOTA, COLOMBIA
    Torres, C.
    Jaramillo, J.
    Coronell, W.
    Gutierrez, M., V
    Caceres, H. A.
    VALUE IN HEALTH, 2011, 14 (07) : A538 - A538
  • [9] FINANCIAL ANALYSIS OF A VACCINATION CAMPAIGN USING 13 VALENT PNEUMOCOCAL CONJUGATED VACCINE (PCV13) WITH EMPLOYERS
    Ferreira, C. N.
    Manfrin, D. F.
    Rufino, C. S.
    VALUE IN HEALTH, 2014, 17 (03) : A270 - A270
  • [10] BUDGET IMPACT EVALUATION OF A VACCINATION WITH CAMPAIGN PROGRAM FOR CORPORATIONS USING PNEUMOCOCCAL CONJUGATED VACCINE (PCV) 13 VALENT VERSUS PNEUMOCOCCAL POLISACCHARIDE VACCINE (PPV) 23 WITH PAID CAMPAIGN FOR OLDER ADULTS
    Fujii, R. K.
    Presa, J.
    Roberts, C. S.
    Gea, Y.
    Manfrin, D. F.
    Mould, J.
    VALUE IN HEALTH, 2013, 16 (03) : A84 - A85
123